Our Team

  • Kenneth Wang

    CEO

    Experienced investor and Entrepreneur

  • Gregory P. Ho

    Chairman

    President & CCO at SMC

  • Colin Ng, MS

    Vice President

    VP at IsoPlexis, Blavatnik Fellow at Yale University

  • Jeffrey Sabina

    Director of R&D

    Extensive R&D leadership experience from IsoPlexis, Detect, QuantumSi and Thermo

  • Jennifer Garbarino, PhD

    Principal Scientist

    Yale PhD with a focus on epigenetic mechanisms

  • Dan Massucci

    Operations Manager

    Senior Biomedical Engineer and Project Lead at IsoPlexis

Board of Directors

  • Kenneth Wang

    Experienced investor and Entrepreneur

    Mr. Wang has worked in the chemicals and life sciences industry as an engineer, management consultant, investment banker and entrepreneur for over 30 years. He gained hands-on experience as a process engineer, served on the Board of Managers of Aristech Acrylics (Mitsubishi Corporation) and helped found two advanced materials companies with defense and life science applications. Following senior investment banking positions at CS First Boston and JP Morgan, he became a financial advisor to small entrepreneurial companies as well as to multinationals (GE Plastics, ITOCHU, Marubeni, Mitsui). Projects include acquisitions that brought sales of Mitsubishi’s U.S. food ingredients business from startup to over $500 million.

  • Gregory P. Ho, Chairman

    President and Head of Opportunity Zones at SMC

    Mr. Ho is the President of Spring Mountain Capital, LP and one of its founding partners. Prior to joining Spring Mountain in 2001, Mr. Ho was a Principal and Chief Financial Officer of McKinsey. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group. Mr. Ho also was a member of the firm’s Investment Committee and a Trustee of McKinsey’s Profit-Sharing Retirement Plan (PSRP). In these capacities, he oversaw the identification, evaluation, and selection of traditional and alternative asset managers and investments for over $1 billion of assets managed by the McKinsey Investment Office (MIO). Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine.

    Mr. Ho is a member of the boards of directors of IsoPlexis, Inc. and ReNetX Bio, Inc., as well as other non-life science companies. He received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College.

  • John L. (Launny) Steffens

    Founder and Senior Management Director at SMC

    Mr. Steffens is the Founder and Senior Managing Director of Spring Mountain. Prior to founding Spring Mountain in 2001, Mr. Steffens spent 38 years at Merrill Lynch & Co., Inc., where he held numerous senior management positions, including President of Merrill Lynch Consumer Markets, Vice Chairman of Merrill Lynch & Co., Inc., and Chairman of its U.S. Private Client Group. Under his leadership, the Private Client Group experienced tremendous growth, increasing assets under management from $200 billion to $1.6 trillion. Mr. Steffens also served on the board of directors of Merrill Lynch & Co., Inc. from April 1986 until July 2001.

  • Richard Andersson

    Associate Director of Business Development at Yale’s OCR

    Mr. Andersson carries out activities leading to the commercialization of technologies invented in the Faculty of Arts and Sciences at Yale University. These activities include identification of transferable technologies, development of commercialization strategies and negotiation of licenses and collaborative R&D agreements.

Scientific Advisory Board

  • Rong Fan, PhD, Founder and Chair of SAB

    Professor of Biomedical Engineering at Yale

    Dr. Fan is the founder of AtlasXomics and is the recipient of numerous awards including the Howard Temin Pathway to Independence award from NCI and the Packard Fellowship for Science and Engineering, He received a Ph.D. in Chemistry from the University of California at Berkeley, and later worked in Professor James Heath’s group at Caltech. His recent work is centered on the development of single-cell omics technologies to analyze deep functional cellular heterogeneity in human cancers and the immune system. He is the co-founder of IsoPlexis and Singleron Biotechnologies.

  • Jennifer Chayes, PhD

    Associate Provost of Data Science and Information, and Dean of the School of Information, at UC Berkeley

    Before joining Berkeley, Dr. Chayes was at Microsoft for over 20 years, where she was Technical Fellow, and founder and managing director of three interdisciplinary labs: Microsoft Research New England, New York City, and Montreal. She has received numerous awards for both leadership and scientific contributions, including the Anita Borg Institute Women of Vision Leadership Award, the John von Neumann Award of the Society for Industrial and Applied Mathematics, and an honorary doctorate from Leiden University. She is a member of the American Academy of Arts and Sciences and the National Academy of Sciences.

  • James R. Heath, PhD

    President and Professor at Institute for Systems Biology in Seattle and Professor of Molecular and Medical Pharmacology at UCLA

    Dr. Heath has directed the National Cancer Institute-funded NSB Cancer Center since 2005. He received his PhD in 1988 from Rice University, where he was the principal graduate student involved in the discovery of C60 and the fullerenes — work that resulted in three senior members of his group receiving the Nobel Prize in Chemistry in 1996. Dr. Heath has founded or cofounded several companies, including PACT Pharma, Integrated Diagnostics, Indi Molecular, CTI Molecular Imaging (acquired by Siemens in 2005), Sofie Biosciences, IsoPlexis, and NanoSys.

  • Jerry S.H. Lee, PhD

    Associate Professor of Clinical Medicine and Chemical Engineering & Material Sciences at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and Chief Science and Innovation Officer for the Lawrence J. Ellison Institute for Transformative Medicine of USC

    Prior to joining USC, Dr. Lee served for more than a decade as a Health Sciences Director within the National Cancer Institute’s Office of the Director. In 2016, Dr. Lee was assigned to Office of the Vice President to serve as the Deputy Director for Cancer Research and Technology for the White House Cancer Moonshot Task Force.

  • Arnold J. Levine, PhD

    Professor Emeritus at the Institute for Advanced Study in Princeton

    Dr. Arnold and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. Dr. Levine established the Simons Center for Systems Biology at the Institute for Advanced Study, concentrating on research at the interface of molecular biology and the physical sciences. He helped shape U.S. science priorities as chairman of an influential 1996 review panel on federal AIDS research funding. He also chaired the National Cancer Advisory Board, which advises the National Academy of Sciences and its Institute of Medicine on cancer policy.